HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Prostaglandin E2

HCID 5280360
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
22230-04-2
Standard SMILES
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O
InChIKey
XEYBRNLFEZDVAW-ARSRFYASSA-N
Molecular formula
C20H32O5
Average molar mass
352.5 g/mol
Monoisotopic mass
352.22497412

Overview

Prostaglandin E2 is prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. It has a role as an oxytocic, a mouse metabolite and a human metabolite. It is a conjugate acid of a prostaglandin E2(1-).

Names & identifiers

Preferred name
Prostaglandin E2
IUPAC
(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
English name
dl-PGE2
Molecular formula
C20H32O5
Molecular weight
352.47

Names & synonyms

Prostaglandin E2Dinoprostone363-24-6PGE2Prostin E2PrepidilCervidilMinprostin E2PropessMinprositin E2DinoprostonDinoprostonum
Show more names
dl-PGE2Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11α,13E,15S)-(+-)-Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11α,13E,15S)-(±)- (9CI)5-Heptenoic acid, 7-[3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl]-, (+-)- (8CI)
CerviprostDinoprostonaEnzaprost ECerviprimeProstenonePGE2alphaU-12062(5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid

Database identifiers

CAS
22230-04-2、363-24-6
PubChem CID
5280360
DTXSID
DTXSID00859353
ChEMBL
CHEMBL548

Properties

Computed structural properties

XLogP
2.8
Topological polar surface area
94.8 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
5
Rotatable bonds
12
Heavy atoms
25
Formal charge
0
Complexity
469

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LipidsFatty Acyls [FA] -> Eicosanoids [FA03] -> Prostaglandins [FA0301]
LogP · 2 items

2.82

2.9

Human Drugs · 4 items

Breast Feeding; Lactation; Milk, Human; Oxytocics; Prostaglandins

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Medicines administered to the neonate [c]

Melting Point67 °C
Physical DescriptionSolid
Dissociation Constants4.77
Collision Cross Section · 3 items

188.9 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Calculation: Single Field; Dataset: Oxylipins]

192.06 Ų [M-H]- [CCS Type: DT; Method: stepped-field]

183.57 Ų [M-H2O-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 79 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

Adverse Effects · 1 item

The most common side effects of prostaglandin E2 concern its impact on gastrointestinal smooth muscle. The suppository correlates with the most severe side effects, with two-thirds of patients experiencing vomiting, two-fifths experiencing diarrhea, and one-third experiencing nausea. Other adverse effects include temperature elevation in half of the patients, headache in one-tenth, and shivering and chills in one-tenth. Anti-emetics and anti-diarrheal medications may be necessary before and during the drug administration to counteract these side effects.

Toxicity SummaryProstaglandin E2 overdose typically manifests as uterine hyperstimulation, and stopping the drug is the most effective treatment. Also, beta-adrenergic drugs, such as terbutaline, may be used in case of continued symptoms.
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Chemistry & industry

Pharmacology

ATC Code · 4 items

G02AD02

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

G02AD02

Protein Binding73%, to albumin
Pharmacodynamics · 1 item

Dinoprostone is equivalent to prostaglandin E2 (PGE2). It stimulates labor and delivery by stimulating the uterine, and thus terminates pregnancy. Dinoprostone is also capable of stimulating the smooth muscle of the gastrointestinal tract of man. This activity may be responsible for the vomiting and/or diarrhea that is not uncommon when dinoprostone is used to terminate pregnancy.

Mechanism of Action · 1 item

Dinoprostone administered intravaginally stimulates the myometrium of the gravid uterus to contract in a manner that is similar to the contractions seen in the term uterus during labor, resulting in the evacuation of the products of conception from the uterus. It is believed that dinoprostone exerts its uterine effects via direct myometrial stimulation, but the exact mechanism of action is unkown. Other suggested mechanisms include the regulation of cellular membrane calcium transport and of intracellular concentrations of cyclic 3',5'-adenosine monophosphate. Dinoprostone also appears to produce local cervical effects including softening, effacement, and dilation. The exact mechanism of action for this effect is also unknown, but it has been suggested that this effect may be associated with collagen degradation caused by secretion of the enzyme collagenase as a partial response to locally administered dinoprostone.

Biological Half-LifeLess than 5 minutes.
Metabolism/MetabolitesRapid metabolism of dinoprostone occurs primarily in the local tissues; any systemic absorption of the medication is cleared mainly in the maternal lungs and, secondarily, at sites such as the liver and kidneys.
FDA Pharmacological Classification · 6 items

Related reactions

42 records
New reaction record
HRID 55567 reaction equation
HRID 55567As reactant
HRID 436346 reaction equation
HRID 436346As reactant
HRID 436347 reaction equation
HRID 436347As reactant
HRID 437096 reaction equation
HRID 437096As reactant
HRID 437107 reaction equation
HRID 437107As reactant
HRID 457460 reaction equation
HRID 457460As product
HRID 549508 reaction equation
HRID 549508As product
HRID 619392 reaction equation
HRID 619392As product
PreviousPage 1 of 6

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEBI
CHEBI:15551
UNII
K7Q1JQR04M
EC Number
206-656-6
Nikkaji
J9.243F

Physicochemical properties

Boiling point
530.1 · 530.1±50.0 °C(Predicted)
Density
1.148 · 1.148±0.06 g/cm3(Predicted)
pka
4.75 · 4.75±0.10(Predicted)

K7Q1JQR04M

DINOPROSTONE

Established Pharmacologic Class [EPC] - Prostaglandin Analog

Chemical Structure [CS] - Prostaglandins

Dinoprostone is a Prostaglandin Analog.

DINOPROSTONE

MeSH Pharmacological Classification · 1 item

Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157)

Absorption, Distribution and Excretion · 2 items

Absorbed at a rate of 0.3 mg per hour over 12 hours while the vaginal system is in place.

The major route of elimination of the products of PGE2 metabolism is the kidneys.

Tissue LocationsBrain
Cellular LocationsCytoplasm
Metabolite PathwaysAcetaminophen Action Pathway

Uses & manufacturing

UsesUse (kg) in USA (2002): 2
Additional notes · 1 item

DefinitionChEBI: Prostaglandin E2 is prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. It has a role as an oxytocic, a human metabolite and a mouse metabolite. It is a conjugate acid of a prostaglandin E2(1-).